We undertook a prospective randomized clinical trial comparing TIPS to peritoneovenous (PV) shunts in the treatment of medically intractable ascites to establish relative efficacy and morbidity, and thereby superiority, between these shunts. Methods: Thirty-two patients were prospectively randomized to undergo TIPS or peritoneovenous (Denver) shunts. All patients had failed medical therapy. Results: After TIPS versus peritoneovenous shunts, median (mean Ϯ SD) duration of shunt patency was similar: 4.4 months (6 Ϯ 6.6 months) versus 4.0 months (5 Ϯ 4.6 months). Assisted shunt patency was longer after TIPS: 31.1 months (41 Ϯ 25.9 months) versus 13.1 months (19 Ϯ 17.3 months) (P Ͻ 0.01, Wilcoxon test). Ultimately, after TIPS 19% of patients had irreversible shunt occlusion versus 38% of patients after peritoneovenous shunts. Survival after TIPS was 28.7 months (41 Ϯ 28.7 months) versus 16.1 months (28 Ϯ 29.7 months) after peritoneovenous shunts. Control of ascites was achieved sooner after peritoneovenous shunts than after TIPS (73% vs. 46% after 1 month), but longer-term efficacy favored TIPS (eg, 85% vs. 40% at 3 years). Conclusion: TIPS and peritoneovenous shunts treat medically intractable ascites. Absence of ascites after either is uncommon. PV shunts control ascites sooner, although TIPS provides better longterm efficacy. After either shunt, numerous interventions are required to assist patency. Assisted shunt patency is better after TIPS. Treating medically refractory ascites with TIPS risks early shuntrelated mortality for prospects of longer survival with ascites control. This study promotes the application of TIPS for medically intractable ascites if patients undergoing TIPS have prospects beyond short-term survival. (Ann Surg 2004;239: 883-891) From the
M edically intractable ascites due to cirrhosis imparts significant morbidity. As well, because it is a manifestation of advanced cirrhosis and represents a presentation of end-stage liver disease, it is generally thought to presage death due to liver failure with relatively small 1-year and 2-year rates of survival. 1, 2 Therefore, interventions for medically intractable ascites are directed at palliating the symptoms of massive ascites while hopefully not hastening hepatic failure. Numerous interventions for medically refractory ascites have been applied, and great debate exists over which is best. Each intervention has advocates and alleged differences in efficacy and differing profiles in complications. In short, after failing medical management, there is no consensus which interventional therapy provides the best palliation with the least morbidity.
Transjugular intrahepatic portasystemic stent shunts (TIPS) have been embraced by many in the treatment of complicated portal hypertension due to cirrhosis. The care and course of thousands of patients with cirrhosis and portal hypertension undergoing TIPS have been reported. TIPS are thought by many to adequately decompress portal hypertension and thereby relieve ascites. [3] [4] [5] [6] [7] [8] TIPS are commonly known to be complicated by issues of shunt patency and progressive hepatic dysfunction.
Peritoneovenous (PV) shunts have been applied to medically intractable ascites for many years. Several large series have been reported. 9 -12 PV shunts are embraced by some because they do not interfere with portal blood flow when decompressing ascites into the systemic venous circulation. Like TIPS, PV shunts are not without their potential problems, such as shunt occlusion and infection.
To establish superiority of TIPS or PV shunts, we implemented a prospective randomized clinical trial for patients with medically intractable ascites. Our hypothesis in undertaking this trial was that PV shunts would provide superior palliation for medically intractable ascites with fewer complications because of a lesser association with occlusion. We also believed that patients undergoing PV shunts would live longer, as they would avoid hepatic consequences of diminished portal blood flow.
METHODS
With institutional review board approval, patients with medically intractable ascites were randomized to undergo TIPS or PV shunts. Maximum medical therapy was defined as 6 months of fluid restriction to 1500 mL per day, salt restriction to 80 mmol per day, 160 mg/day of furosemide, and 300 mg/day of spironolactone. Medically intractable ascites was defined as the persistence of massive ascites despite maximum medical therapy or with intolerance to medical therapy because of azotemia. Consent for this trial was obtained prior to randomization to undergo TIPS or PV shunt. Patients were randomized to allow for analysis by pair differences.
The peritoneovenous shunts used were regular flow Denver shunts. Cultures of peritoneal fluid were obtained preoperatively to document sterile peritoneal fluid. With general anesthesia, they were placed using percutaneous techniques. Large-volume paracentesis was undertaken with PV shunt placement with replacement of the ascitic fluid with normal saline. The venous tip of the PV shunt was placed into the right atrium.
Our technique of TIPS placement has been described. 13 If a significant volume of ascites was present, it was drained using a pigtail intraperitoneal catheter prior to the TIPS procedure. With ultrasound guidance, the right internal jugular vein was cannulated and an 11-Fr hemostatic sheath was placed into the inferior vena cava. The right hepatic vein was cannulated using a selective catheter and over a wire a curved metal cannula device was advanced into the right hepatic vein. The cannula multiple passes were made through the liver parenchyma using a sharp needle until access to the right portal vein was achieved. A wire was passed through the needle into the portal vein followed by a catheter. Portal venous pressures and hepatic vein pressures were measured and contrast portal venography was done to assess the location of the entrance site into the portal vein as well as to evaluate for varices. If the access is adequate, the parenchymal tract was dilated to 8 mm with a noncompliant angioplasty balloon. Then an 8-mm Wallstent endoprosthesis (Boston Scientific Corp., Natick, MA) was placed bridging the right portal vein and the right hepatic vein. Repeat 8-mm balloon angioplasty was undertaken to fully expand the stent. Pressures in the portal vein and right hepatic vein were remeasured and portal venography was repeated. Portal veinright hepatic vein pressure gradients of 8 mm Hg or less were sought using an 8-mm stent. If the gradient was above 12 mm Hg, the 8-mm Wallstent was balloon dilated to 10 mm to decrease the gradient. The patients were monitored in the intensive care unit overnight for instability related to fluid volume shifts or increased load on the right side of the heart.
One to 3 days after TIPS placement, color-flow Doppler ultrasound was undertaken to document shunt patency and evaluate flow. Disturbances in flow through the stent were followed by transjugular venography and pressure measurements and, if indicated, balloon dilation, stent replacement, or additional stent placement.
After shunting, ascites was defined as absent, controlled, or refractory. Ascites was absent if not clinically apparent without medical therapy. Ascites was controlled if not clinically apparent with medical therapy. Ascites was refractory if voluminous or causing morbidity, despite medical therapy.
Prior to discharge after shunting, patients were reintroduced to their medical regimen, including diuretic therapy. Their medical regimen was adjusted based upon clinical well-being. Patients were followed through clinic visits. Patients were seen within 2 weeks of shunt placement and at least every 6 months thereafter. Patients failing to appear for clinic visits were sought. Ascites recurrence was documented. Diuretic needs were documented. Shunt patency was documented.
Patients undergoing TIPS underwent color-flow Doppler ultrasound at 3 and 6 months, 1 year, and biannually thereafter. Abnormalities in portal blood flow through or near the stent were followed by transjugular venography and pressure measurements, with interventions as indicated for stenosis/occlusion or stent foreshortening. PV shunt patency was determined by clinical examination or by Tc 99 sulfur colloid injection into the peritoneal cavity. PV shunts were deduced to be patent if ascites was absent or controlled and, if by palpation, the Denver shunt pump chamber felt soft and was compressible. With questions of patency, Tc 99 colloid was injected into the peritoneal cavity and evidence of flow through the shunt was sought.
If shunt stenosis or occlusion could be corrected, even if it required an additional shunt, it was. "Assisted shunt patency" denoted a patent shunt though shunt revisions or replacement occurred. Shunt failure was defined as refractory ascites with shunt patency, irreversible shunt occlusion with the inability to place/replace an additional shunt, or death directly due to consequences of shunt placement or shunting. Even though all the patients in this trial had poor predicted survival because of their underlying cirrhosis and relatively end-stage liver disease, survival after shunting was recorded.
Along with demographic data, pertinent preshunt laboratory data were recorded. Pertinent laboratory data were recorded at follow-up.
The Model for End-stage Liver Disease (MELD) was used to compare the groups of patients undergoing TIPS or PV shunts. 14, 15 MELD was also used to predict survival of patients undergoing either shunt and to allow for comparisons between patients undergoing TIPS or PV shunts.
All data were stored on an Excel spreadsheet (Microsoft, Redmond, WA). All data are reported as mean Ϯ SD, when appropriate. Nonparametric data are reported as median and mean Ϯ SD. All statistical analyses were undertaken on True Epistat (Epistat Services, Richardson, TX). Significance was accepted with 95% probability.
RESULTS
Thirty-two patients were randomized to undergo TIPS or PV shunts ( Table 1 ). There were no notable differences between patients undergoing TIPS or PV shunts. Three patients undergoing TIPS had serum bilirubin levels over 6 mg/dL, causing the mean level to seem elevated more than for patients undergoing PV shunts. All had failed maximum medical therapy. All patients were of Child's class C. Predicted survival was not different between patients undergoing PV shunts or TIPS (P ϭ 0.74, Mantel-Haenszel 2 : prospective studies) ( Table 2) .
TIPS were successfully undertaken in 16 patients without notable event. One patient developed a hepatic artery aneurysm as a consequence of TIPS placement. The artery and aneurysm were embolized without consequence. TIPS significantly decreased portal pressures and portal vein-inferior vena cava pressure gradients in all patients ( Table 3) . After TIPS, in-hospital shunt patency was 88%, median shunt patency was 4.4 months, and mean shunt patency was 6 Ϯ 6.6 months. After TIPS, median assisted shunt patency was 31.1s month and mean assisted shunt patency was 41 Ϯ 25.9 months.
With follow-up after TIPS, malfunction was noted in 12 (75%) patients because of stenosis or occlusion. TIPS revisions were undertaken in 10 patients at various intervals (Table 4 ). Overall, 24 shunt revisions were undertaken in 10 patients. Ultimately, irreversible shunt occlusion occurred in 19% of patients undergoing TIPS.
PV shunts were undertaken without notable morbidity in 16 patients. After PV shunts, in-hospital shunt patency was 94%, median shunt patency was 4.0 months, and mean shunt patency was 5 Ϯ 4.6 months. After PV shunts, median assisted shunt patency was 13.1 months and mean assisted shunt patency was 19 Ϯ 17.3 months. Shunt malfunction after PV shunts was noted in 14 patients, generally because of occlusion (9 patients) or infection requiring shunt removal (5 patients) (Table 5 ). Overall, 25 revisions were undertaken in 12 patients. PV shunts were removed from 6 patients. Seven patients required placement of additional PV shunts. Assisted shunt patency after PV shunt was less than after TIPS (P Ͻ 0.01, Wilcoxon test). Ultimately, irreversible shunt occlusion occurred in 38% of patients with PV shunts.
PV shunts improved ascites in 80% of patients by 1 month after placement versus in 54% of patients after TIPS (Table 6 ). By 3 months after placement, TIPS improved ascites in 67%. By 1 year, ascites was controlled for 56% of patients after PV shunts and for 80% of patients after TIPS. 
By 3 years, PV shunts provided control of ascites in 40%
while TIPS provided control of ascites in 86%. At 5 years, in an ever-decreasing number of patients at risk, TIPS provided control of ascites for 100% of patients, while PV shunts provided control of ascites in no patients (less than after TIPS, log-likelihood ratio test, P ϭ 0.006). From 12 through 60 months, TIPS provided better control of ascites than did PV shunts (Mantel-Haenszel 2 : prospective studies, P ϭ 0.023) ( Table 6 ). Conversely, after TIPS ascites remained refractory in 46% at 1 month. This decreased to 14% at 3 years. Refractory ascites after TIPS was not noted for patients at 5 years. After PV shunts, ascites was refractory in 20% at 1 month and increased to 60% at 3 years. Refractory ascites was noted in all patients after PV shunts at 5 years, albeit in a small number of patients at risk ( Table 6 ).
Absence of ascites was not noted for any patients after either shunt beyond 1 month after shunt placement with follow-up through 5 years.
After TIPS, 1 patient with irreversible shunt occlusion underwent PV shunting. After PV shunting, 1 patient with irreversible shunt occlusion underwent TIPS.
Survival for patients undergoing TIPS or PV shunts was recorded. Survival was compared with predicted survival (Table 7) . Four patients remain alive after TIPS and 2 remain alive after PV shunts. After TIPS, survival was 81% at 1 month. Median survival after TIPS was 28.7 months and mean survival was 41 Ϯ 28.7 months. After PV shunts, survival was 94% at 1 month. Median survival after PV shunts was 16.1 months and mean survival was 28 Ϯ 29.7 months. Survival after TIPS was similar to predicted survival but compared favorably beyond 1 month after TIPS (Table  7) . Survival after PV shunts was not different than predicted survival, but unlike after TIPS, compared favorably early after shunting (Table 7) . Survival at 1 year through 5 years seems to favor TIPS relative to PV shunts, but differences are not significant (P ϭ 0.26, Mantel-Haenszel 2 : prospective studies)
After TIPS, 10 deaths were due to liver failure and were possibly hastened by shunting (Table 8 ). After TIPS, 2 additional deaths resulted from variceal bleeding. After PV shunts, 3 deaths resulted from sepsis, and 7 deaths resulted from liver failure ( Table 8 ). One patient died 70 months after TIPS. Three patients remain alive with controlled ascites at 106 months, 103 months, and 92 months after TIPS. Two patients are alive after PV shunts: 1 with an occluded shunt and refractory ascites at 87 months and 1 whose PV shunt was removed at 13 months because of subclavian vein stenosis and superior vena cava thrombosis.
Failure of shunting occurred in 12 patients after TIPS and in all 16 patients after PV shunts. After TIPS, 12 patients 
DISCUSSION
Some aspects of the management of voluminous ascites resulting from advanced cirrhosis are well established and without debate. Fluids and salt should be restricted. Diuretics, including furosemide and spironolactone, should be applied. For those failing these indicated measures, the management of medically intractable ascites is debated. Different approaches have strong proponents. Several randomized trials have been undertaken, but conclusions have been conflicting and no trials have compared TIPS to other forms of procedural decompression beyond repeated large-volume paracentesis. Through this prospective, comparative trial, the efficacy and risks of TIPS relative to peritoneovenous shunting are established. This trial further defines the clinical role of TIPS in portal decompression and, thereby, controlling medically intractable ascites.
The patients of this trial were generally middle-aged men with end-stage cirrhosis resulting from excessive alcohol consumption or hepatitis. Our definition of intractable ascites is consistent with the broad scope of literature on this subject and is consistent with focused reports. 16 We have written about this previously. 17 MELD Scores reflect a relatively favorable population of patients, with median and mean scores well superior to scores consistent with 1-year median survival. 14, 15 Predicted survival was over 50% at 1 year and nearly that at 2 years (Table 2) . Nonetheless, MELD scores and modeling denote a group of patients with expected survival much below an age-and gender-matched general population.
The patients of this trial consented to the protocol and the randomization prior to randomization to receive either TIPS or PV shunts. No patients refused further care through the protocol after randomization. Both TIPS and PV shunts were undertaken concomitant with large-volume paracentesis to give both groups of patients a similar start in the treatment of their intractable ascites. Both shunts were placed without notable event, although a potentially life-threatening hepatic artery aneurysm was noted 1 week after TIPS and embolized without event.
TIPS, unlike the PV shunts, directly and significantly decreased portal pressures (Table 3) . Portal decompression might be more aggressive today than when this trial was initiated, knowing what we now know of the long-term efficacy and complications of TIPS. More aggressive decompression should lead to lower portal pressures and, thereby, better control of ascites. However, more aggressive portal decompression might well be associated with increased rates and occurrences of progressive hepatic decompensation and failure, a major complicating issue with TIPS. The decompression achieved in this trial was very similar to the portal decompression achieved with TIPS in other trials. 8, 18, 19 PV shunts, unlike TIPS, acted to directly decompress ascites. With PV shunts, a major issue in function is location of the tip of the shunt. We worked diligently to place the shunt tip in the right atrium, but errors in placement and tip migration are a concern. Shunt tip placement in the superior vena cava, rather than in the right atrium, might impair shunt function, although we don't believe any such impairment would be monumental if the tip is close to the atrium. A majority of patients underwent revisions of their shunts. After TIPS, nearly 2 of 3 patients underwent shunt revisions despite early deaths occurring within 1 month of shunting in nearly 1 in 5 patients. Furthermore, many patients underwent more than one TIPS revision. Stenosis and occlusion is the "Achilles' heel" of the TIPS shunt. Other studies confirm that our rate of stenosis and occlusion, while high, is not uncommon. In a trial evaluating the efficacy of TIPS in treating ascites, 8 with mean follow-up at only 70 weeks, 32% of patients had undergone revisions of their TIPS shunts and only 47% of patients were alive with patent shunts and controlled ascites free of encephalopathy. In a similar trial, 130 shunt stenoses were noted in 85 patients, 65% of the patients in the trial, with median follow-up of 23.7 months. 7 As in our trial, stent stenosis and occlusion was rectified radiologically.
After PV shunts, three fourths of the patients underwent interventions to maintain a patent shunt. This generally involved PV shunt replacement or replacement of the venous end or peritoneal end of the shunt. As after TIPS, many patients underwent more than one PV shunt revision. Like after TIPS, most revisions were necessitated by occlusion or stenosis. Unlike after TIPS, some of the revisions or removals of PV shunts were to treat shunt infections. Overall, assisted shunt patency was significantly longer after TIPS than after PV shunts: median assisted shunt patency was nearly 2.5 times longer and mean assisted shunt patency was more than double.
Both shunts acted to control ascites. However, no patients were absent of ascites beyond 1 month of shunting with follow-up through 5 years. Although statistically significant differences in shunt efficacy were seldom achieved, PV shunts seemed better at ascites control early after shunting. TIPS was better at ascites control later (1-5 years) after shunting. As well, a higher percentage of patients had refractory ascites at 5 years after PV shunts than after TIPS because of irreversible shunt failure and a trend toward higher mortality. In a retrospective review of our earlier experience with PV shunts, removal or revisions of PV shunts was frequent because of infection or dysfunction (most common). Less than half of the patients in that report were palliated at death or at most recent follow-up. 9 Predicted survival was very close to actual survival. As previously noted, ascites is not an independent predictor of mortality in the MELD model. 14, 15 Rather, it is a redundant measure of end-stage liver disease, adding negligibly to other measures (eg, creatinine, bilirubin, and prothrombin time) of liver function and patient well-being. Ascites is a consequence of end-stage liver disease, not an independent predic-tor of survival for patients with end-stage liver disease. Although no statistical differences in survival were noted after TIPS versus PV shunts, there was a trend toward more early mortality after TIPS and a trend toward more late mortality after PV shunts.
Deaths after either shunt were common and generally due to hepatic failure. Mortality after either shunt was likely. Less than 1 in 5 patients remained alive after 5 years. TIPS may have hastened hepatic failure, but that would be conjecture and speculation as there were no significant differences in survival after either shunt, either in timing or cause. Notably, fatal sepsis was seen only after PV shunts. Longterm (5-year) survival with a patent shunt was quite uncommon at just more than 1 in 10 patients and was seen only after TIPS.
Mortality after TIPS in this study is not excessive given reports of similar patients. 7, 8, 14, 15, 20 In developing the MELD model, the patient population used experienced 70 (30%) deaths within 3 months of TIPS in 231 patients. 14 Other studies note similar survivals: 54% at 6 months, 48% at 1 year, and 39% at 2 years, 8 48% at 1 year, 21 and 58% at 2 years. 4 A meta-analysis of mortality after TIPS for refractory ascites documents a pooled 1-year survival rate of 56%. 20 Some studies contained patients undergoing liver transplantation to avoid fatal hepatic decompensation and, thereby, postshunt mortality was improved. 4 Further studies had awful survival after TIPS (26%-29% at 2 years) and do not seem to represent anticipated outcomes after TIPS. 3, 5 As in our study, death in all studies of TIPS is most commonly due to liver failure. Notably, other studies 4 -6,8,20 note a significant occurrence (more than 20%) of clinically apparent encephalopathy, which we did not see in any of our patients.
In this study, mortality after PV shunts is not excessive given reports of similar patients. Rather, mortality after PV shunts in this study seems quite good. In a previous report, we detailed our experience with PV shunts in an entirely different group of patients. In that retrospective report, 32 of 48 patients died after shunting, with death coming within 5 months on average and without palliation of ascites in 40%. 9 Not very impressive. Furthermore, as previously mentioned, less than half of the patients in that report were palliated at death or at most recent follow-up. 9 None of the patients in this trial underwent transplantation, which was not available in Tampa at the time of this trial. Although intractable ascites can be an indication for transplantation, it is seldom a sole indication. With this in mind, relative to peritoneovenous shunts, TIPS seems to provide a superior "bridge" to transplantation. This is in contradistinction to TIPS as opposed to surgical shunts when treating portal hypertension.
What about MELD? Does it work? Is it applicable to this study? It was developed to stratify risk for patients undergoing elective TIPS procedures. 14 ous function of total bilirubin, prothrombin time (stated as International Normalized Ratio), and creatinine developed to predict survival for patients undergoing elective TIPS procedures. MELD was modified, by dropping the cause of cirrhosis, to be more generally applicable in assigning probability of survival and stratifying risk for patients with cirrhosis. 15 MELD is thought to work best in predicting chances of survival over a short time: 3 months might be best, 14 but 2 years seems acceptable 15 and 3 years might be a reach. It seems that the accuracy of MELD falls off with time, and it progressively understates predicted mortality. Nonetheless, MELD seems more accurate than the Child-Pugh score in predicting survival after TIPS. 7, 21, 22 Other scoring systems have been compared with MELD and have been found to be lacking. 22 MELD is not subject to interobserver variation in assigning risk of interventions that other scoring systems, like the Child-Pugh Score, are.
A MELD Score of 18 is thought to be the score for a median survival of 3 months. 14 Others have found the score for 3-month median survival to be lower (ie, 14). 21 Certainly some error is involved with any scoring method and an error rate of up to even 25% can be expected. While such an error rate seems high, and it is, it cannot be unexpected.
There are limitations to MELD. It is most useful for patients with advanced liver disease. Better measures of liver and renal disease could undoubtedly improve the quality of MELD. The effects of older age, gender, dehydration, BMI, drug therapy, stress, and short-term starvation cannot be ignored, although their impact seems statistically negligible if patients are hemodynamically stable and clinically euvolemic.
CONCLUSION
We have not supported the hypotheses of our trial. All patients undergoing PV shunts failed shunting by 5 years and had probably failed soon after 3 years. After TIPS, survival beyond 5 years with a patent shunt occurs in 1 in 4 with close observation and follow-up and with frequent interventions to maintain shunt patency. Beyond an insignificant trend in earlier relief of ascites, for patients with prospects for survival beyond 3 months (ie, a MELD score less than 18), there is little to recommend PV shunting and TIPS should be preferentially applied. For patients without prospects for survival beyond 3 months, liver transplantation is best applied. PV shunting in the treatment of intractable ascites should be generally reserved for patients without prospects for survival beyond 3 months who are not candidates for transplantation.
First, Dr. Rosemurgy, is that how you really feel at the end of this? I certainly haven't done a peritoneovenous shunt now for 10 years, and I think TIPS has to a large extent replaced it and I think your documentation in this randomized trial does go a long way to finalizing that decision. I do, however, have a few other questions.
What else do we learn from this study other than the high complication rates and minimal early release the peritoneovenous shunt did give? TIPS clearly is one of the options in managing this group of patients. But there are caveats. And I think you clearly document the high rate of stenosis and the high reintervention rate required to keep TIPS patent. Your reintervention rate, like ours (as far as using TIPS for bleeding as well ascites), is in the 75% range at 1 year. TIPS works if you monitor them closely. And I think that is the issue.
I note that you did not appear to have protocol recatheterization studies of TIPS in this particular trial. We have. And it has been surprising that ultrasound can look fine but the gradients are high. And TIPS doesn't work if the gradient is over 10 to 12 million of mercury. And the data tend to show you need a lower gradient group to manage your ascites compared to variceal bleeders. As I look at your manuscript and your protocol for follow-up, the reintervention rates are appropriate just monitoring with ultrasound.
I would have some questions. I think the standard of care seemed to change, and recatheterization probably will become part of the standard of care of TIPS in either 6 months or a year, which is the high-risk time for restenosis.
Your irreversible occlusion rate of 19% is also somewhat higher than literature values. Certainly, our approach is if they are irreversibly occluded to put in a parallel second TIPS for those patients. I wonder if you have considered doing that in any of those patients? Or were these irreversible occlusions some of the patients that died in the TIPS group in the study?
My second point relates to the MELD score. I applaud you for using the MELD score-for the rest of the audience, this is the model for end-stage liver disease-replacing the Child's score in categorizing severity of liver disease. It was originally developed to look at prognosis and outcome in patients undergoing TIPS. It has become the standard for liver transplant.
What does surprise me a bit in this trial is the low MELD scores. Your starting point in MELD scores is 6. Most of your transplant patients being transplanted MELD score 18 to the 20s. Your mean MELD scores run at about 9 here. Again, this is one of the issues. To go back to Child's score, intractable ascites is pushing you toward the Child's C in a hurry.
Creatinine is one of the biggest drivers of MELD scores. And neither in your presentation nor in the manuscript have you got the actual creatinine values. Intractable ascites, diuretics, tend to push up the creatinine. The implication to me, without knowing the absolute numbers, is your mean creatinines must have been less than 1.4 to 1.5 in this group. Particularly intractable ascites was unusual. I do think using MELD scores is correct. But my second question relates to: what were the serum creatinines really like in this group of patients?
My final comment really relates to the absence of liver transplant in this trial. The other randomized trial looking at TIPS for the management of ascites, the multicenter study that compared it to large-volume paracentesis, kind of fell short because so many patients entered into that trial were transplanted. As far as I could ascertain, none of the 32 patients entering into this trial came to transplant. Was the listing for transplant a contraindication to getting into this study? Or is it just that your Tampa population is different, they are all active alcoholic non-candidates for transplant? Because clearly end-stage liver disease, the management, if they are candidates, is transplant, yet that wasn't a feature in this trial. So comment on why transplant in the future would be helpful as well.
DR. LAYTON F. RIKKERS (MADISON, WISCONSIN): First, I would like to compliment Dr. Rosemurgy for continuing to attempt to answer some very important questions in this field that has become over the past decade or 2 increasingly nonsurgical.
Despite the fact that this trial was a bit underpowered with only 16 patients in each group, I think he has convincingly shown us that the peritoneovenous shunt is basically dead and that the TIPS is the preferred procedure for the small percentage of patients, and I emphasize it is a small percentage of patients, that develop medically intractable ascites.
Did any of these patients have the hepatorenal syndrome? Many patients with medically intractable ascites tend to have rising BUN and creatinines and slip off into the hepatorenal syndrome. Were any of your patients going in this direction? And what was the impact of the peritoneovenous shunt or the TIPS on that syndrome? Second, one of the great disadvantages in most of the randomized control trials of the TIPS is that, although effective in preventing variceal bleeding at least until they become dysfunctional, they do function as nonselective side-to-side shunts. In these trials, there is an incidence of encephalopathy of approximately 25% after TIPS. Did you observe encephalopathy in any of your patients?
DR. THOMAS R. GADACZ (AUGUSTA, GEORGIA): I just have 2 questions: One, although it was a small number of patients (16) , did you see any complications, particularly coagulopathy, in the peritoneovenous shunt patients? The second question is: did you look at any cost data? Are we getting a bigger Catheterization studies for the patients undergoing TIPS. We routinely undertake catheterization studies at 1 year, 3 years, 5 years, somewhere between 5 and 10 years, I will say 7 years.
Reversible occlusion: 19% of the patients have had reversible occlusion of TIPS in this report. That is high, but it is a small number of patients. And some of the patients were too sick to undergo revisions, they wouldn't give consent to undergo revisions or they were being put into a transplant program at that time, and it was thought that if transplantation was imminent it, was not worthwhile doing revisions of the TIPS. If we were aggressive enough, we probably could increase the median shunt patency rate in patients that underwent TIPS, that would work to increase the differences between the patients undergoing TIPS and peritoneovenous shunts.
With regard to the MELD model, as you know, ascites is not an independent predictor of outcome in the MELD model, and so it is not a surprise, if you will, that the MELD numbers are relatively low in the patients that have tense ascites. Ascites seems to be more of a manifestation of liver disease than a predictor of outcome. Ascites does not necessarily occur in patients with bad liver function per se and thereby measures of bilirubin and prothrombine time might not predict who is going to get ascites. But the patients in our trial did have relatively good predicted survival and were able to, after TIPS, stay on that survival curve.
Serum creatinines weren't mentioned. But they were obviously quite good because the MELD scores were quite low. Patients were seldom transplanted in this trial as an endpoint because these patients didn't have funding, they were alcoholics, or they failed the transplant evaluation process for other reasons: psychological support, social support, and so on.
Hepatorenal syndrome did not occur in any of the patients that underwent care in this trial, in part because the trial was designed to look at long-term palliation as opposed to heroic measures in patients that have hepatorenal syndrome. I do believe that TIPS and even possibly the peritoneovenous shunt have some role in the acute rescue of patients that have hepatorenal syndrome.
Encephalopathy was not seen in any of the patients, again consistent with low MELD scores of 9. If a patient did have a fixed encephalopathy, I would suggest that that would move them quickly to imminent transplantation. If people have a medically manageable encephalopathy, then I think that the reasons for more definitive transplantation would be based upon the other issues involved.
In terms of costs, the big issue with TIPS is the number of revisions. Patients that have bleeding varices or have had bleeding varices that stenosis: rehemorrhage, readmissions, and so on. In this trial, since revisions were quite frequent in both groups, there probably is no difference in cost, although you might argue that peritoneovenous shunts would be less expensive because of more limited survival. But if you look at dollars per year of life, I think that the TIPS is going to be better than peritoneovenous shunts. There seem to be few indications for peritoneovenous shunts after this trial. TIPS is preferable when treating intractable ascites. Peritoneovenous shunts are best applied to patitents who have portal vein thrombosis.
